The modulatory role of dietary vitamin A on the carcinogen metabolizing enzymes was studied in masheri extract and benzo[a]pyrene-treated rats. Weanling male Sprague-Dawley rats were fed vitamin A deficient (SR-) and vitamin A sufficient (SR+) semisynthetic diets for 12 weeks. ME/B[a]P treatment significantly increased the phase I activating enzymes in both SR- and SR+ groups. However, a higher percentage increase in enzyme activities was observed in both liver and lung of the SR- animals compared to the SR+ groups. Glutathione content and activity of glutathione S-transferase were decreased in both liver and lung of SR- animals on treatment with either ME or B[a]P. In the SR+ group, an increase in GSH content and GST activity was observed following the ME/B[a]P treatment. The hepatic pool of vitamin A was depleted while that of vitamin C was increased after ME or B[a]P treatment in both SR- and SR+ groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0885-4505(90)90059-a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol
January 2025
GOG Foundation, Florida Cancer Specialists and Research Institute, West Palm Beach, FL 33401, United States of America. Electronic address:
Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy.
View Article and Find Full Text PDFEffect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.
EClinicalMedicine
October 2024
Centre for Psychedelic Research, Division of Psychiatry, Department Brain Sciences, Imperial College London, United Kingdom.
Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.
Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.
Contrast-enhanced ultrasound as a valuable tool to detect minimal inflammation in RA patients in sustained remission.
Front Med (Lausanne)
December 2024
Rheumatology Department, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal.
Objective: The study aimed to explore the utility of contrast-enhanced ultrasound (CEUS) as a tool for detecting minimal inflammation in rheumatoid arthritis (RA) patients in sustained remission (SR) and to correlate the findings with Disease Activity Score 28 (DAS28) status scores and various ultrasound (US) scores.
Patients And Methods: Thirty RA patients in SR (minimum 6 months), 12 with active disease, and 10 healthy controls were included. Clinical evaluations and US assessments were performed, including grayscale US (GSUS), power Doppler US (PDUS), and Global OMERACT-EULAR Synovitis Score (GLOESS).
CANAIRI: the Collaboration for Translational Artificial Intelligence Trials in healthcare.
Nat Med
January 2025
Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Nat Med
January 2025
Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA.
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!